ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. is not very popular among insiders. ACADIA Pharmaceuticals Inc. is a mediocre stock to choose.
Log in to see more information.
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and...

News

Bank of New York Mellon Corp Grows Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Bank of New York Mellon Corp Grows Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Ticker Report Bank of New York Mellon Corp increased its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 4.5% in the 2nd quarter, according to its most recent 13F filing with the...\n more…

Acadia (ACAD) Up 10% Since Last Earnings Report: Can It Continue?
Acadia (ACAD) Up 10% Since Last Earnings Report: Can It Continue?

Zacks Investment Research A month has gone by since the last earnings report for Acadia Pharmaceuticals (ACAD). Shares have added about 10% in that time frame, outperforming the S&P 500.Will the recent positive trend continue...\n more…

Allspring Global Investments Holdings LLC Purchases 49,992 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Allspring Global Investments Holdings LLC Purchases 49,992 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Ticker Report Allspring Global Investments Holdings LLC raised its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 85.0% during the second quarter, according to its most recent...\n more…

Short Interest in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Decreases By 7.4%
Short Interest in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Decreases By 7.4%

Ticker Report ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) was the target of a large decrease in short interest during the month of August. As of August 15th, there was short interest totalling...\n more…

Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $25.56
Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $25.56

Zolmax ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) has earned an average rating of "Moderate Buy" from the sixteen analysts that are covering the company, Marketbeat reports. Five research...\n more…

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Average Recommendation of "Moderate Buy" from Brokerages
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Average Recommendation of "Moderate Buy" from Brokerages

Ticker Report Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) have been given a consensus rating of "Moderate Buy" by the sixteen research firms that are currently covering the firm...\n more…